Bicycle Therapeutics ADR

At the company’s ordinary general meeting, all submitted proposals were approved by the required majority. Felix Baker and Hervé Hoppenot were re-elected as directors. Executive remuneration, the appointment of PricewaterhouseCoopers as auditor for 2026, and the annual financial statements and remuneration reports for 2025 were approved. In total, 49,696,908 ordinary shares were represented, about 98.64% of the outstanding capital. » More on de.investing.com

RBC Capital lowered its price target on Bicycle Therapeutics to $7 from $11, citing the company's pivot away from zelenectide as a near-term setback that reduces commercialization visibility, while maintaining a Sector Perform rating. Oppenheimer also trimmed its target to $36 and kept an Outperform rating as Bicycle shifts resources to BT5528 and next‑generation programs including radio‑conjugates. The company reported Q4 EPS of -$0.29 versus a -$0.95 consensus and revenue of $47.96m (driven by recognized collaboration revenue after partner terminations) and announced restructuring plans including a proposed workforce reduction. » More on finance.yahoo.com

Bicycle Therapeutics announced several leadership changes: Travis Thompson will become chief financial officer, succeeding Alethia Young, who will remain for a three-month transition before moving into an advisory role. Michael Method has been promoted to chief medical officer; Eric Westin is retiring but will stay with the company as a Distinguished Fellow; and Michael Skynner is moving into the role of chief scientific officer. The company says the new management will drive development of its innovative Bicycle molecules and its clinical oncology pipeline. Bicycle Therapeutics reports it has funding expected to last through 2028 and plans to expand targeted study programs and strategic partnerships in radiopharmaceuticals. » More on de.investing.com